Alnylam Pharmaceuticals | ALNY - Passivo Circulante





Passivo Circulante Alterar Data
Acadia Pharmaceuticals USD 305.52M 28.41M 2026-03
Agios Pharmaceuticals USD 58.84M 23.36M 2026-03
Alnylam Pharmaceuticals USD 1.35B 116.87M 2026-03
Amgen USD 24.96B 534M 2026-03
Arrowhead Research USD 295.22M 52.2M 2026-03
BioCryst Pharmaceuticals USD 195.39M 675K 2026-03
BioMarin Pharmaceutical USD 793.15M 34.12M 2026-03
Incyte USD 1.49B 25.52M 2026-03
Ionis Pharmaceuticals USD 717M 66M 2026-03
Moderna USD 2.4B 408M 2026-03
Neurocrine Biosciences USD 831.7M 88.3M 2026-03
Novartis USD 27.28B 4.72B 2025-12
PTC Therapeutics USD 923.6M 44.82M 2026-03
Regeneron Pharmaceuticals USD 5.11B 739.3M 2026-03
Sangamo BioSciences USD 47.66M 1.9M 2025-06
Sanofi EUR 28.35B 9.32B 2025-12
Sarepta Therapeutics USD 499.16M 596.13M 2026-03
Takeda JPY 2.43T 180.65B 2026-03
Tectonic Therapeutic USD 12.96M 3.29M 2026-03
Ultragenyx Pharmaceutical USD 325M 59M 2026-03
Vertex Pharmaceuticals USD 3.88B 19.4M 2026-03
Xencor USD 73.46M 22.45M 2026-03